Novartis signs $1.3bn deal with UK-based Dunad
Dunad will apply its own platform to generate the novel covalent and targeted protein degrading small molecule drugs
Read MoreDunad will apply its own platform to generate the novel covalent and targeted protein degrading small molecule drugs
Read MoreBack in 2019, esketamine was commercialised as Spravato, described as a “breakthrough” medication used to treat depression
Read MoreBamlanivimab and etesevimab are intended for use in COVID patients at high risk of disease progression
Read MoreIndonesia becomes the first country to authorise the vaccine
Read MoreBelgium leads in country rankings by the value of exports this year, followed by Germany and the US
Read More




PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
